Loading...
Market
Will a larger clinical trial for the LSCD stem-cell treatment start in Japan by Q1 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial registries or announcements from research institutions
Story
World-First Stem-Cell Treatment Restores Vision to 20/20 for Four Patients with Limbal Stem Cell Deficiency in Japan
Nov 8, 2024, 09:42 PM
A groundbreaking treatment using corneal epithelial cell sheets derived from human induced pluripotent stem cells (iPSCs) has restored vision in patients with limbal stem cell deficiency (LSCD). This world-first procedure was conducted in Japan as part of a single-arm, open-label, first-in-human interventional study. Four individuals with damaged corneas received the stem-cell transplants, and initial results indicate that the treatment is safe, although further testing in larger trials is necessary. Notably, one patient, previously legally blind, has achieved better than 20/20 vision following the procedure. The study highlights the potential of stem-cell therapies in restoring vision and addressing severe ocular conditions.
View original story
Similar markets
Japan • 25%
USA • 25%
EU • 25%
Other • 25%
0-4 • 25%
5-9 • 25%
10-14 • 25%
15 or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant tooth regrowth • 25%
Moderate tooth regrowth • 25%
Minimal tooth regrowth • 25%
No tooth regrowth • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
